Adaptive Biotechnologies signed two multi‑year agreements with Pfizer to license its T‑cell receptor (TCR) discovery platform and TCR‑antigen mapping data. Under the first agreement, Pfizer will use Adaptive’s immune medicine platform to identify disease‑causing TCRs for rheumatoid arthritis, with potential milestone and commercial payments that could total about $890 million. A second data‑access agreement gives Pfizer rights to TCR‑antigen datasets to train AI models and accelerate R&D across multiple disease areas. Adaptive receives upfront payments and potential future annual licensing fees under both pacts. The deals exemplify how large pharmas are paying for immune‑receptor intelligence and data to de‑risk target selection and to power next‑generation immunotherapies and diagnostics.